📢 #ESMO21 E-poster: "HER2-low breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment" by Dr. Miglietta @vitti10 @GaiaGriguolo HER2-low expression showed high instability from primary BC to RD after neoadjuvant treatment